Peer-reviewed veterinary case report
Signs and treatment outcomes in cats with throat lymphoma
By Ignasi Rodriguez-Piza et al.·Published in Journal of feline medicine and surgery·2023·View original on Semantic Scholar →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Clinical presentation, treatment and outcome in 23 cats with laryngeal or tracheal lymphoma
- Species:
- cat
Plain-English summary
A 12-year-old male cat was diagnosed with laryngeal lymphoma after showing signs of increased effort to breathe and unusual sounds from the upper respiratory tract. The cat underwent chemotherapy and, in some cases, surgery to remove part of the tumor. Remarkably, 65% of the cats treated had a complete response to the treatment, leading to a median survival time of about 2.5 years. This suggests that cats with this type of lymphoma can have a good chance of recovery with the right treatment.
People also search for: cat breathing problems · laryngeal lymphoma treatment in cats · cat cancer survival rates
Abstract
Objectives Feline primary laryngeal or tracheal lymphoma (PLTL) is an uncommon extranodal presentation. Information on long-term survival is scarce, although some small case series describe this being achieved with multiagent protocols; an accurate outcome for cats with PLTL is yet to be determined. The aim of this study was to gather information on the clinical presentation, response to treatment and outcome in a large case series of feline PLTL. Methods This retrospective multicentre study included cats with a cytological or histopathological confirmation of PLTL. Histopathology samples, when available, were reassessed for grade and immunophenotype. Clinical (age, signalment, retroviral status, presence of anaemia, clinical signs, location and therapy type) and outcome (response, progression-free survival [PFS] and overall survival [OS]) variables were recorded. Survival analyses to assess the impact of variables on PFS and OS were performed. Results Twenty-three cases were included; cats had a median age of 11 years (range 2–16) and the male:female ratio was 3.6:1. Common clinical signs at presentation included increased respiratory effort (74%) and abnormal upper respiratory tract sounds (48%). Immunophenotyping was performed in 48% of cases and all were B cell. Debulking surgery was performed in 26% of cases. All cats received chemotherapy, COP (cyclophosphamide, vincristine and prednisolone; 39%), CHOP (cyclophosphamide, vincristine, doxorubicin and prednisolone; 44%) and other protocols (17%); 35% had a partial response and 65% a complete response. Median PFS and OS were 909 days (range 23–1484) and 909 days (range 23–2423), respectively. Complete response was associated with longer PFS (P <0.001) and OS (P = 0.012). Pretreatment with steroids was associated with longer OS (P = 0.003). No other variable was found to be significant. Conclusions and relevance PLTL in cats is mostly of a B-cell phenotype, could be of a low-to-medium grade, and may respond to surgical and medical treatment with a longer survival time than has previously been reported.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on Semantic Scholar: https://www.semanticscholar.org/paper/36655881